Top entities: ADMA Biologics, Rosen Law Firm, Lawrence Rosen, Philip Kim.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 27, 2026. Coverage continues to evolve.

Regulatory class action

ADMA Biologics Securities Class Action

Q: When did this event occur?

First reported Jul 24, 2026; last updated Jul 27, 2026.

Q: What is the market impact?

General. The lawsuit may negatively impact ADMA's stock price and investor confidence.

Analysis based on 7 articles · First reported Jul 24, 2026 · Last updated Jul 27, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The lawsuit may negatively impact ADMA's stock price and investor confidence. Potential financial liability could affect ADMA's market valuation.

Biotechnology

Event Summary

Rosen Law Firm has filed a securities class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The lawsuit alleges that ADMA made false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. The lead plaintiff deadline is August 10, 2026.

Key Actions

80 Rosen Law Firm announced investigation ADMA Biologics

Entities Involved

stock

ADMA Biologics

ADMA Biologics is the defendant in the securities class action, facing allegations of fraud and inadequate disclosures, which could lead to financial damages and reputational harm.

Importance 100.0 Sentiment -40.0

priv

Rosen Law Firm

Rosen Law Firm is the plaintiff's counsel representing investors in the class action, seeking compensation for alleged securities law violations.

Importance 60.0 Sentiment 10.0

per

Lawrence Rosen

Lawrence Rosen is a partner at Rosen Law Firm involved in the case, providing legal representation to the class.

Importance 20.0 Sentiment 5.0

per

Philip Kim

Philip Kim is an attorney at Rosen Law Firm handling the ADMA Biologics class action, serving as a contact for investors.

Importance 10.0 Sentiment 5.0

Relationships

ADMA Biologics related ↔ Rosen Law Firm

Rosen Law Firm related ↔ Lawrence Rosen

Rosen Law Firm related ↔ Philip Kim

Lawrence Rosen managing partner ↔ Philip Kim Lawrence Rosen is the founder and managing partner of Rosen Law Firm, where Philip Kim is a partner, and they actively c

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard